Bruker Corporation has launched a new division dedicated to spatial biology.
- This division merges technologies from NanoString Technologies and Canopy Biosciences.
- The focus is on advancing biomedical research with comprehensive solutions.
- Key platforms include GeoMx®, CosMx™, and CellScape™ for spatial analysis.
- The division’s aim is to offer tailored solutions for unique research needs.
Bruker Corporation has announced a pioneering move with the initiation of its new spatial biology division. This new branch offers a comprehensive suite of industry-leading multiomic spatial biology platforms, designed to enhance scientific exploration globally.
The amalgamation within this division includes NanoString Technologies and Canopy Biosciences, alongside Bruker Spatial Genomics, previously Acuity Spatial Genomics. This strategic coordination aims to leverage the strengths of these entities, significantly bolstering the capabilities available for spatial biology research.
The division is set to push the boundaries of biomedical research by providing a wide array of spatial biology instruments, assays, software, and data analytics. Such resources are complemented by CRO services, enabling researchers to undertake complex studies with increased accuracy and efficiency.
Significant innovations within this division include the integration of NanoString’s GeoMx®, CosMx™, and AtoMx™ products, as well as Canopy Biosciences’ CellScape™ platform. These tools are engineered to address diverse research needs, from spatial genomics to proteomics, ensuring a holistic approach to scientific investigation.
Dr. Mark R. Munch, President of the Bruker NANO group, highlighted the coordinated capabilities of these platforms as ‘best-in-class across spatial genomics, transcriptomics, and proteomics.’ The inclusion of tools like CellScape and NanoString’s nCounter® gene expression analysis represents a significant step towards comprehensive spatial analysis.
Todd Garland, appointed President of the new division, expressed enthusiasm about leading Bruker Spatial Biology. Garland’s goal is to offer tailored solutions to customers, emphasising the avoidance of a ‘one-size-fits-all’ methodology. This approach promises bespoke services across the spectrum of discovery to translational research needs.
Bruker Spatial Biology is set to showcase its cutting-edge technologies at the Society for Immunotherapy of Cancer (SITC) 2024, reflecting its commitment to innovation and leadership within the field.
Bruker’s new division represents a landmark development in spatial biology, fostering innovation and advancing research capabilities.
